Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Elevated systemic levels of the matrix metalloproteinase inhibitor TIMP-1 correlate with clinical markers of cachexia in patients with chronic pancreatitis and pancreatic cancer

Fig. 2

a Analysis of TIMP-1 in plasma samples in PDAC with (n = 10) and without jaundice (n = 26). Shapiro-Wilks testing in combination with visual inspection of the histograms showed that samples were not normally distributed. Groups were compared using nonparametric Mann-Whitney U test for independent variables. b Analysis of TIMP-1 in plasma samples in CP patients with (n = 6) and without cachexia (n = 19), and in PDAC patients with (n = 13) and without cachexia (n = 23). Shapiro-Wilks testing in combination with visual inspection of the histograms showed that samples were not normally distributed. Groups were compared using nonparametric Mann-Whitney U test for independent variables. c Analysis of TIMP-1 in plasma samples in PDAC with (n = 5) and without jaundice (n = 18) (patients with cachexia were excluded). Shapiro-Wilks testing in combination with visual inspection of the histograms showed that samples were normally distributed. Groups were compared using Student’s t-test for independent samples. d Analysis of TIMP-1 in plasma samples in CP patients with (n = 6) and without cachexia (n = 18), and in PDAC patients with (n = 8) and without cachexia (n = 18) (patients with jaundice were excluded). Shapiro-Wilks testing in combination with visual inspection of the histograms showed that samples were normally distributed. Groups were compared using Student’s t-test for independent samples

Back to article page